comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-29 22:50:24 - browse：3

A crowd of miniature figurines facing towards an hourglass. -- cancer coverage from STAT — Adobe

It’s no secret that a lucky few seem to glide into old age, the years settling gracefully on their bodies, while others appear to have been dragged through time tied to a metaphorical garbage truck. Biologists have been developing numerous ways to measure the rate an individual ages — often called an accelerated or decelerated “biological age” — and trying to translate it into a heightened or reduced risk of the morbidity and mortality that comes with aging.

There’s been a proliferation of various biological aging clocks, mathematical models that look at things like genetic markers or proteins in your body to make some estimation of an individual’s biological age. Research interest in using these clocks has exploded. In the last five years, thousands of papers on or incorporating the clocks have been published. The paper describing one popular biological aging clock, PhenoAge, has over 1,800 citations alone. One recent study suggested that a reason cancer incidence is increasing among younger adults may be accelerated aging, based on this particular clock.

But as scientists use these clocks to associate biological age with specific health risks, like cancer or dementia, and numerous companies eagerly offer biological age measurements in exchange for hundreds of bucks, it may be worth noting that experts don’t agree on what “biological age” actually is.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Smaller biotechs seek to piggyback on weight loss drug boom

WSS

STAT Summit: How researchers deal with rejection

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Questions loom on AstraZeneca cancer drug as safety concerns ebb

What it’s like to watch children die of measles

Smaller biotechs seek to piggyback on weight loss drug boom

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

explore

23andMe had bad news about my health. I wish a person had delivered it

With psoriasis trial ahead, Alumis raises $259 million

23andMe had bad news about my health. I wish a person had delivered it

Roche drug slashes death risk in early

What does generative AI mean for health care? We asked experts

Roivant's CEO is a star, but biotech's black hole persists

DIEP, the 'gold standard' of breast reconstruction, is under threat

Results on Novartis prostate cancer therapy could expand its use

Medicare details structure of new drug price negotiation program

Change Healthcare payments predicted restored March 15

focus

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Why a market frenzy over new weight loss drugs defies logic

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Is there really a nursing shortage in the U.S.?

How to bring more disabled researchers into academia

NEJM study link tiny plastics in blood vessels to heart problems

focus

Wikipedia

focus

leisure time